Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...